Investors

Company Profile

Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.

Financial Reports

Q3 Report 2020

November 5, 2020

Q2 Half Year Report 2020

August 6, 2020

Q1 Report 2020

May 5, 2020

Investor presentations

SVB Leerink Presentation Feb 24, 2021

Corporate Deck February 2021

Corporate Deck January 2021

JPM Presentation Jan 14, 2021

Investor Deck December 2020

Additional Phase 3 PRIMROSE 1 and 2 Study Results Confirming Sustained Efficacy and Continued Safety of linzagolix in the Treatment of Uterine Fibroids

Investor Presentation Jefferies Virtual London Healthcare Conference November 18, 2020

Results: PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor

1 2 3

Press Releases

ObsEva Announces Year End 2020 Financial Results and Business Update

press release

March 5, 2021

-Yselty® for uterine fibroids: US New Drug Application filing planned in Q2:21; European marketing approval anticipated in Q4:21- -Yselty® for…

Read more

ObsEva to Present at the H.C. Wainwright Global Life Sciences Conference

press release

March 3, 2021

Geneva, Switzerland and Boston, MA – March 3, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company…

Read more

ObsEva to Present at the SVB Leerink 10th Annual Global Healthcare Conference

press release

February 17, 2021

Geneva, Switzerland and Boston, MA – February 17, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical…

Read more
1 2 3 58

General Meetings

ObsEva Annual General Meeting 2020

June 9, 2020

Read more

ObsEva Annual General Meeting 2019

May 8, 2019

Read more
1 2 3

Upcoming Events

Save the date: ObsEva Annual General Meeting May 28, 2021

Event


    Read more
     

    Contacts

    ObsEva Switzerland Office

    Chemin des Aulx,12

    1228, Plan-Les-Ouates, Geneva, Switzerland

    +41 (0)22 552 3840


    contact@obseva.ch

    ObsEva U.S. Office

    1 Financial Center

    Suite 2440 Boston, MA 02111

    +1 857 972 9364


    contact@obseva.ch

    Media Switzerland & Europe

    Shauna Dillon

    +41 (0)22 552 1550 Office

    +41 79 360 3533 Mobile

    shauna.dillon@obseva.ch

    Media United States

    Shauna Dillon

    +41 (0)22 552 1550 Office

    +41 (0)79 360 3533 Mobile

    shauna.dillon@obseva.ch

    Investor relations


    .


    Joyce Allaire

    +1 (617)-435-6602

    ir@obseva.ch

    Clinical studies




    clinicaltrials@obseva.ch

    HR Office

    Charlotte Cadoux


    charlotte.cadoux@obseva.ch

    CEO Office

    +41 (0)22 552 1550


    shauna.dillon@obseva.ch

     

    Sign up for news

     
     

      * Type:


      InvestorHCPNursePayerHospital PharmacistRetail PharmacistOther












      Read our privacy policy here.


       

      Are you sure you want to leave ObsEva.com?

      We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

      Continue to link

      Disclaimer

      Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

      Continue

      Disclaimer

      Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

      Continue